
Dancann Pharma Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Dancann Pharma
Access all reports
The company, through its subsidiary Kron Medical ApS, develops a portfolio of novel cannabinoid therapies on the basis of patented technology platforms in the areas of pain, cancer, and brain diseases/disorders. It is also developing medicines for the treatment of infantile spasms or seizures; and a class of drugs for the treatment of various conditions caused by redox signalling imbalance. The company was founded in 2015 and is based in Odense, Denmark
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
DANCAN
Country
🇩🇰 Denmark